 | • レポートコード：QYR2104Z3011 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥565,500 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥848,250 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,131,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、IBS治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（IBS-D、IBS-C、IBS-M）、用途別市場規模（病院、クリニック、研究所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・IBS治療の市場動向 ・企業の競争状況、市場シェア ・IBS治療の種類別市場規模（IBS-D、IBS-C、IBS-M） ・IBS治療の用途別市場規模（病院、クリニック、研究所） ・IBS治療の北米市場規模2016-2027（アメリカ、カナダ） ・IBS治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・IBS治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・IBS治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・IBS治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Allergan Plc (Ireland)、Sucampo Pharmaceuticals (U.S.)、Ironwood Pharmaceuticals, Inc. (U.S.)、Astellas Pharma Inc. (Japan)、Bausch Health、Abbott Laboratories (U.S.)、Synergy Pharmaceuticals, Inc. (U.S.)、Ardelyx, Inc. (U.S.)、Nestle (Switzerland)、Sebela Pharmaceuticals (Ireland)、Probi (Sweden)、Alfasigma USA, Inc. (Italy)、RedHill Biopharma Ltd. (Israel)、AstraZeneca (U.K)、Ipsen (France)、Novartis AG (Switzerland)、Takeda Pharmaceutical Company Ltd (Japan)、Synthetic Biologics, Inc. (U.S.)、Protagonist Therapeutics Inc. (U.S.)、Pfizer Inc (U.S.)、Lexicon Pharmaceuticals, Inc. (U.S.)、Innovate Biopharmaceuticals (U.S.)） ・結論 |
Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
Market Analysis and Insights: Global IBS Treatment Market
The global IBS Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global IBS Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global IBS Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global IBS Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global IBS Treatment market.
Global IBS Treatment Scope and Market Size
IBS Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global IBS Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
IBS-D
IBS-C
IBS-M
Segment by Application
Hospitals
Clinics
Research Laboratories
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Allergan Plc (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals, Inc. (U.S.)
Astellas Pharma Inc. (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals, Inc. (U.S.)
Ardelyx, Inc. (U.S.)
Nestle (Switzerland)
Astellas Pharma Inc. (Japan)
Bausch Health
Alfasigma USA, Inc. (Italy)
RedHill Biopharma Ltd. (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis AG (Switzerland)
Takeda Pharmaceutical Company Ltd (Japan)
Synthetic Biologics, Inc. (U.S.)
Protagonist Therapeutics Inc. (U.S.)
Pfizer Inc (U.S.)
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 IBS-D
1.2.3 IBS-C
1.2.4 IBS-M
1.3 Market by Application
1.3.1 Global IBS Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global IBS Treatment Market Perspective (2016-2027)
2.2 IBS Treatment Growth Trends by Regions
2.2.1 IBS Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 IBS Treatment Historic Market Share by Regions (2016-2021)
2.2.3 IBS Treatment Forecasted Market Size by Regions (2022-2027)
2.3 IBS Treatment Industry Dynamic
2.3.1 IBS Treatment Market Trends
2.3.2 IBS Treatment Market Drivers
2.3.3 IBS Treatment Market Challenges
2.3.4 IBS Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top IBS Treatment Players by Revenue
3.1.1 Global Top IBS Treatment Players by Revenue (2016-2021)
3.1.2 Global IBS Treatment Revenue Market Share by Players (2016-2021)
3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by IBS Treatment Revenue
3.4 Global IBS Treatment Market Concentration Ratio
3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2020
3.5 IBS Treatment Key Players Head office and Area Served
3.6 Key Players IBS Treatment Product Solution and Service
3.7 Date of Enter into IBS Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IBS Treatment Breakdown Data by Type
4.1 Global IBS Treatment Historic Market Size by Type (2016-2021)
4.2 Global IBS Treatment Forecasted Market Size by Type (2022-2027)
5 IBS Treatment Breakdown Data by Application
5.1 Global IBS Treatment Historic Market Size by Application (2016-2021)
5.2 Global IBS Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America IBS Treatment Market Size (2016-2027)
6.2 North America IBS Treatment Market Size by Type
6.2.1 North America IBS Treatment Market Size by Type (2016-2021)
6.2.2 North America IBS Treatment Market Size by Type (2022-2027)
6.2.3 North America IBS Treatment Market Size by Type (2016-2027)
6.3 North America IBS Treatment Market Size by Application
6.3.1 North America IBS Treatment Market Size by Application (2016-2021)
6.3.2 North America IBS Treatment Market Size by Application (2022-2027)
6.3.3 North America IBS Treatment Market Size by Application (2016-2027)
6.4 North America IBS Treatment Market Size by Country
6.4.1 North America IBS Treatment Market Size by Country (2016-2021)
6.4.2 North America IBS Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe IBS Treatment Market Size (2016-2027)
7.2 Europe IBS Treatment Market Size by Type
7.2.1 Europe IBS Treatment Market Size by Type (2016-2021)
7.2.2 Europe IBS Treatment Market Size by Type (2022-2027)
7.2.3 Europe IBS Treatment Market Size by Type (2016-2027)
7.3 Europe IBS Treatment Market Size by Application
7.3.1 Europe IBS Treatment Market Size by Application (2016-2021)
7.3.2 Europe IBS Treatment Market Size by Application (2022-2027)
7.3.3 Europe IBS Treatment Market Size by Application (2016-2027)
7.4 Europe IBS Treatment Market Size by Country
7.4.1 Europe IBS Treatment Market Size by Country (2016-2021)
7.4.2 Europe IBS Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific IBS Treatment Market Size (2016-2027)
8.2 Asia-Pacific IBS Treatment Market Size by Type
8.2.1 Asia-Pacific IBS Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific IBS Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific IBS Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific IBS Treatment Market Size by Application
8.3.1 Asia-Pacific IBS Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific IBS Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific IBS Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific IBS Treatment Market Size by Region
8.4.1 Asia-Pacific IBS Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific IBS Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America IBS Treatment Market Size (2016-2027)
9.2 Latin America IBS Treatment Market Size by Type
9.2.1 Latin America IBS Treatment Market Size by Type (2016-2021)
9.2.2 Latin America IBS Treatment Market Size by Type (2022-2027)
9.2.3 Latin America IBS Treatment Market Size by Type (2016-2027)
9.3 Latin America IBS Treatment Market Size by Application
9.3.1 Latin America IBS Treatment Market Size by Application (2016-2021)
9.3.2 Latin America IBS Treatment Market Size by Application (2022-2027)
9.3.3 Latin America IBS Treatment Market Size by Application (2016-2027)
9.4 Latin America IBS Treatment Market Size by Country
9.4.1 Latin America IBS Treatment Market Size by Country (2016-2021)
9.4.2 Latin America IBS Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa IBS Treatment Market Size (2016-2027)
10.2 Middle East & Africa IBS Treatment Market Size by Type
10.2.1 Middle East & Africa IBS Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa IBS Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa IBS Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa IBS Treatment Market Size by Application
10.3.1 Middle East & Africa IBS Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa IBS Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa IBS Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa IBS Treatment Market Size by Country
10.4.1 Middle East & Africa IBS Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa IBS Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Allergan Plc (Ireland)
11.1.1 Allergan Plc (Ireland) Company Details
11.1.2 Allergan Plc (Ireland) Business Overview
11.1.3 Allergan Plc (Ireland) IBS Treatment Introduction
11.1.4 Allergan Plc (Ireland) Revenue in IBS Treatment Business (2016-2021)
11.1.5 Allergan Plc (Ireland) Recent Development
11.2 Sucampo Pharmaceuticals (U.S.)
11.2.1 Sucampo Pharmaceuticals (U.S.) Company Details
11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
11.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
11.3 Ironwood Pharmaceuticals, Inc. (U.S.)
11.3.1 Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
11.3.2 Ironwood Pharmaceuticals, Inc. (U.S.) Business Overview
11.3.3 Ironwood Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
11.3.4 Ironwood Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.3.5 Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
11.4 Astellas Pharma Inc. (Japan)
11.4.1 Astellas Pharma Inc. (Japan) Company Details
11.4.2 Astellas Pharma Inc. (Japan) Business Overview
11.4.3 Astellas Pharma Inc. (Japan) IBS Treatment Introduction
11.4.4 Astellas Pharma Inc. (Japan) Revenue in IBS Treatment Business (2016-2021)
11.4.5 Astellas Pharma Inc. (Japan) Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Details
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health IBS Treatment Introduction
11.5.4 Bausch Health Revenue in IBS Treatment Business (2016-2021)
11.5.5 Bausch Health Recent Development
11.6 Abbott Laboratories (U.S.)
11.6.1 Abbott Laboratories (U.S.) Company Details
11.6.2 Abbott Laboratories (U.S.) Business Overview
11.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
11.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.6.5 Abbott Laboratories (U.S.) Recent Development
11.7 Synergy Pharmaceuticals, Inc. (U.S.)
11.7.1 Synergy Pharmaceuticals, Inc. (U.S.) Company Details
11.7.2 Synergy Pharmaceuticals, Inc. (U.S.) Business Overview
11.7.3 Synergy Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
11.7.4 Synergy Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.7.5 Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
11.8 Ardelyx, Inc. (U.S.)
11.8.1 Ardelyx, Inc. (U.S.) Company Details
11.8.2 Ardelyx, Inc. (U.S.) Business Overview
11.8.3 Ardelyx, Inc. (U.S.) IBS Treatment Introduction
11.8.4 Ardelyx, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.8.5 Ardelyx, Inc. (U.S.) Recent Development
11.9 Nestle (Switzerland)
11.9.1 Nestle (Switzerland) Company Details
11.9.2 Nestle (Switzerland) Business Overview
11.9.3 Nestle (Switzerland) IBS Treatment Introduction
11.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2016-2021)
11.9.5 Nestle (Switzerland) Recent Development
11.10 Sebela Pharmaceuticals (Ireland)
11.10.1 Sebela Pharmaceuticals (Ireland) Company Details
11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
11.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2016-2021)
11.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
11.11 Probi (Sweden)
11.11.1 Probi (Sweden) Company Details
11.11.2 Probi (Sweden) Business Overview
11.11.3 Probi (Sweden) IBS Treatment Introduction
11.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2016-2021)
11.11.5 Probi (Sweden) Recent Development
11.12 Alfasigma USA, Inc. (Italy)
11.12.1 Alfasigma USA, Inc. (Italy) Company Details
11.12.2 Alfasigma USA, Inc. (Italy) Business Overview
11.12.3 Alfasigma USA, Inc. (Italy) IBS Treatment Introduction
11.12.4 Alfasigma USA, Inc. (Italy) Revenue in IBS Treatment Business (2016-2021)
11.12.5 Alfasigma USA, Inc. (Italy) Recent Development
11.13 RedHill Biopharma Ltd. (Israel)
11.13.1 RedHill Biopharma Ltd. (Israel) Company Details
11.13.2 RedHill Biopharma Ltd. (Israel) Business Overview
11.13.3 RedHill Biopharma Ltd. (Israel) IBS Treatment Introduction
11.13.4 RedHill Biopharma Ltd. (Israel) Revenue in IBS Treatment Business (2016-2021)
11.13.5 RedHill Biopharma Ltd. (Israel) Recent Development
11.14 AstraZeneca (U.K)
11.14.1 AstraZeneca (U.K) Company Details
11.14.2 AstraZeneca (U.K) Business Overview
11.14.3 AstraZeneca (U.K) IBS Treatment Introduction
11.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2016-2021)
11.14.5 AstraZeneca (U.K) Recent Development
11.15 Ipsen (France)
11.15.1 Ipsen (France) Company Details
11.15.2 Ipsen (France) Business Overview
11.15.3 Ipsen (France) IBS Treatment Introduction
11.15.4 Ipsen (France) Revenue in IBS Treatment Business (2016-2021)
11.15.5 Ipsen (France) Recent Development
11.16 Novartis AG (Switzerland)
11.16.1 Novartis AG (Switzerland) Company Details
11.16.2 Novartis AG (Switzerland) Business Overview
11.16.3 Novartis AG (Switzerland) IBS Treatment Introduction
11.16.4 Novartis AG (Switzerland) Revenue in IBS Treatment Business (2016-2021)
11.16.5 Novartis AG (Switzerland) Recent Development
11.17 Takeda Pharmaceutical Company Ltd (Japan)
11.17.1 Takeda Pharmaceutical Company Ltd (Japan) Company Details
11.17.2 Takeda Pharmaceutical Company Ltd (Japan) Business Overview
11.17.3 Takeda Pharmaceutical Company Ltd (Japan) IBS Treatment Introduction
11.17.4 Takeda Pharmaceutical Company Ltd (Japan) Revenue in IBS Treatment Business (2016-2021)
11.17.5 Takeda Pharmaceutical Company Ltd (Japan) Recent Development
11.18 Synthetic Biologics, Inc. (U.S.)
11.18.1 Synthetic Biologics, Inc. (U.S.) Company Details
11.18.2 Synthetic Biologics, Inc. (U.S.) Business Overview
11.18.3 Synthetic Biologics, Inc. (U.S.) IBS Treatment Introduction
11.18.4 Synthetic Biologics, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.18.5 Synthetic Biologics, Inc. (U.S.) Recent Development
11.18 Protagonist Therapeutics Inc. (U.S.)
.1 Protagonist Therapeutics Inc. (U.S.) Company Details
.2 Protagonist Therapeutics Inc. (U.S.) Business Overview
.3 Protagonist Therapeutics Inc. (U.S.) IBS Treatment Introduction
.4 Protagonist Therapeutics Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
.5 Protagonist Therapeutics Inc. (U.S.) Recent Development
11.20 Pfizer Inc (U.S.)
11.20.1 Pfizer Inc (U.S.) Company Details
11.20.2 Pfizer Inc (U.S.) Business Overview
11.20.3 Pfizer Inc (U.S.) IBS Treatment Introduction
11.20.4 Pfizer Inc (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.20.5 Pfizer Inc (U.S.) Recent Development
11.21 Lexicon Pharmaceuticals, Inc. (U.S.)
11.21.1 Lexicon Pharmaceuticals, Inc. (U.S.) Company Details
11.21.2 Lexicon Pharmaceuticals, Inc. (U.S.) Business Overview
11.21.3 Lexicon Pharmaceuticals, Inc. (U.S.) IBS Treatment Introduction
11.21.4 Lexicon Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.21.5 Lexicon Pharmaceuticals, Inc. (U.S.) Recent Development
11.22 Innovate Biopharmaceuticals (U.S.)
11.22.1 Innovate Biopharmaceuticals (U.S.) Company Details
11.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
11.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
11.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2016-2021)
11.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global IBS Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of IBS-D
Table 3. Key Players of IBS-C
Table 4. Key Players of IBS-M
Table 5. Global IBS Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global IBS Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global IBS Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global IBS Treatment Market Share by Regions (2016-2021)
Table 9. Global IBS Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global IBS Treatment Market Share by Regions (2022-2027)
Table 11. IBS Treatment Market Trends
Table 12. IBS Treatment Market Drivers
Table 13. IBS Treatment Market Challenges
Table 14. IBS Treatment Market Restraints
Table 15. Global IBS Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global IBS Treatment Market Share by Players (2016-2021)
Table 17. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS Treatment as of 2020)
Table 18. Ranking of Global Top IBS Treatment Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by IBS Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players IBS Treatment Product Solution and Service
Table 22. Date of Enter into IBS Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 25. Global IBS Treatment Revenue Market Share by Type (2016-2021)
Table 26. Global IBS Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global IBS Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global IBS Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global IBS Treatment Revenue Market Share by Application (2016-2021)
Table 30. Global IBS Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global IBS Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 33. North America IBS Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America IBS Treatment Market Size by Application (2016-2021) (US$ Million)
Table 35. North America IBS Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America IBS Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America IBS Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe IBS Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe IBS Treatment Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe IBS Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe IBS Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe IBS Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific IBS Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific IBS Treatment Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific IBS Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific IBS Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific IBS Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America IBS Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America IBS Treatment Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America IBS Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America IBS Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America IBS Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa IBS Treatment Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa IBS Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa IBS Treatment Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa IBS Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa IBS Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa IBS Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 62. Allergan Plc (Ireland) Company Details
Table 63. Allergan Plc (Ireland) Business Overview
Table 64. Allergan Plc (Ireland) IBS Treatment Product
Table 65. Allergan Plc (Ireland) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 66. Allergan Plc (Ireland) Recent Development
Table 67. Sucampo Pharmaceuticals (U.S.) Company Details
Table 68. Sucampo Pharmaceuticals (U.S.) Business Overview
Table 69. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product
Table 70. Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 71. Sucampo Pharmaceuticals (U.S.) Recent Development
Table 72. Ironwood Pharmaceuticals, Inc. (U.S.) Company Details
Table 73. Ironwood Pharmaceuticals, Inc. (U.S.) Business Overview
Table 74. Ironwood Pharmaceuticals, Inc. (U.S.) IBS Treatment Product
Table 75. Ironwood Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 76. Ironwood Pharmaceuticals, Inc. (U.S.) Recent Development
Table 77. Astellas Pharma Inc. (Japan) Company Details
Table 78. Astellas Pharma Inc. (Japan) Business Overview
Table 79. Astellas Pharma Inc. (Japan) IBS Treatment Product
Table 80. Astellas Pharma Inc. (Japan) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 81. Astellas Pharma Inc. (Japan) Recent Development
Table 82. Bausch Health Company Details
Table 83. Bausch Health Business Overview
Table 84. Bausch Health IBS Treatment Product
Table 85. Bausch Health Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 86. Bausch Health Recent Development
Table 87. Abbott Laboratories (U.S.) Company Details
Table 88. Abbott Laboratories (U.S.) Business Overview
Table 89. Abbott Laboratories (U.S.) IBS Treatment Product
Table 90. Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 91. Abbott Laboratories (U.S.) Recent Development
Table 92. Synergy Pharmaceuticals, Inc. (U.S.) Company Details
Table 93. Synergy Pharmaceuticals, Inc. (U.S.) Business Overview
Table 94. Synergy Pharmaceuticals, Inc. (U.S.) IBS Treatment Product
Table 95. Synergy Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 96. Synergy Pharmaceuticals, Inc. (U.S.) Recent Development
Table 97. Ardelyx, Inc. (U.S.) Company Details
Table 98. Ardelyx, Inc. (U.S.) Business Overview
Table 99. Ardelyx, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 100. Ardelyx, Inc. (U.S.) Recent Development
Table 101. Nestle (Switzerland) Company Details
Table 102. Nestle (Switzerland) Business Overview
Table 103. Nestle (Switzerland) IBS Treatment Product
Table 104. Nestle (Switzerland) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 105. Nestle (Switzerland) Recent Development
Table 106. Sebela Pharmaceuticals (Ireland) Company Details
Table 107. Sebela Pharmaceuticals (Ireland) Business Overview
Table 108. Sebela Pharmaceuticals (Ireland) IBS Treatment Product
Table 109. Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 110. Sebela Pharmaceuticals (Ireland) Recent Development
Table 111. Probi (Sweden) Company Details
Table 112. Probi (Sweden) Business Overview
Table 113. Probi (Sweden) IBS Treatment Product
Table 114. Probi (Sweden) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 115. Probi (Sweden) Recent Development
Table 116. Alfasigma USA, Inc. (Italy) Company Details
Table 117. Alfasigma USA, Inc. (Italy) Business Overview
Table 118. Alfasigma USA, Inc. (Italy) IBS Treatment Product
Table 119. Alfasigma USA, Inc. (Italy) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 120. Alfasigma USA, Inc. (Italy) Recent Development
Table 121. RedHill Biopharma Ltd. (Israel) Company Details
Table 122. RedHill Biopharma Ltd. (Israel) Business Overview
Table 123. RedHill Biopharma Ltd. (Israel) IBS Treatment Product
Table 124. RedHill Biopharma Ltd. (Israel) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 125. RedHill Biopharma Ltd. (Israel) Recent Development
Table 126. AstraZeneca (U.K) Company Details
Table 127. AstraZeneca (U.K) Business Overview
Table 128. AstraZeneca (U.K) IBS Treatment Product
Table 129. AstraZeneca (U.K) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 130. AstraZeneca (U.K) Recent Development
Table 131. Ipsen (France) Company Details
Table 132. Ipsen (France) Business Overview
Table 133. Ipsen (France) IBS Treatment Product
Table 134. Ipsen (France) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 135. Ipsen (France) Recent Development
Table 136. Novartis AG (Switzerland) Company Details
Table 137. Novartis AG (Switzerland) Business Overview
Table 138. Novartis AG (Switzerland) IBS Treatment Product
Table 139. Novartis AG (Switzerland) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 140. Novartis AG (Switzerland) Recent Development
Table 141. Takeda Pharmaceutical Company Ltd (Japan) Company Details
Table 142. Takeda Pharmaceutical Company Ltd (Japan) Business Overview
Table 143. Takeda Pharmaceutical Company Ltd (Japan) IBS Treatment Product
Table 144. Takeda Pharmaceutical Company Ltd (Japan) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 145. Takeda Pharmaceutical Company Ltd (Japan) Recent Development
Table 146. Synthetic Biologics, Inc. (U.S.) Company Details
Table 147. Synthetic Biologics, Inc. (U.S.) Business Overview
Table 148. Synthetic Biologics, Inc. (U.S.) IBS Treatment Product
Table 149. Synthetic Biologics, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 150. Synthetic Biologics, Inc. (U.S.) Recent Development
Table 151. Protagonist Therapeutics Inc. (U.S.) Company Details
Table 152. Protagonist Therapeutics Inc. (U.S.) Business Overview
Table 153. Protagonist Therapeutics Inc. (U.S.) IBS Treatment Product
Table 154. Protagonist Therapeutics Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 155. Protagonist Therapeutics Inc. (U.S.) Recent Development
Table 156. Pfizer Inc (U.S.) Company Details
Table 157. Pfizer Inc (U.S.) Business Overview
Table 158. Pfizer Inc (U.S.) IBS Treatment Product
Table 159. Pfizer Inc (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 160. Pfizer Inc (U.S.) Recent Development
Table 161. Lexicon Pharmaceuticals, Inc. (U.S.) Company Details
Table 162. Lexicon Pharmaceuticals, Inc. (U.S.) Business Overview
Table 163. Lexicon Pharmaceuticals, Inc. (U.S.) IBS Treatment Product
Table 164. Lexicon Pharmaceuticals, Inc. (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 165. Lexicon Pharmaceuticals, Inc. (U.S.) Recent Development
Table 166. Innovate Biopharmaceuticals (U.S.) Company Details
Table 167. Innovate Biopharmaceuticals (U.S.) Business Overview
Table 168. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product
Table 169. Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2016-2021) & (US$ Million)
Table 170. Innovate Biopharmaceuticals (U.S.) Recent Development
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Global IBS Treatment Market Share by Type: 2020 VS 2027
Figure 2. IBS-D Features
Figure 3. IBS-C Features
Figure 4. IBS-M Features
Figure 5. Global IBS Treatment Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Research Laboratories Case Studies
Figure 9. IBS Treatment Report Years Considered
Figure 10. Global IBS Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global IBS Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global IBS Treatment Market Share by Regions: 2020 VS 2027
Figure 13. Global IBS Treatment Market Share by Regions (2022-2027)
Figure 14. Global IBS Treatment Market Share by Players in 2020
Figure 15. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in IBS Treatment as of 2020
Figure 16. The Top 10 and 5 Players Market Share by IBS Treatment Revenue in 2020
Figure 17. Global IBS Treatment Revenue Market Share by Type (2016-2021)
Figure 18. Global IBS Treatment Revenue Market Share by Type (2022-2027)
Figure 19. North America IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America IBS Treatment Market Share by Type (2016-2027)
Figure 21. North America IBS Treatment Market Share by Application (2016-2027)
Figure 22. North America IBS Treatment Market Share by Country (2016-2027)
Figure 23. United States IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe IBS Treatment Market Share by Type (2016-2027)
Figure 27. Europe IBS Treatment Market Share by Application (2016-2027)
Figure 28. Europe IBS Treatment Market Share by Country (2016-2027)
Figure 29. Germany IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific IBS Treatment Market Share by Type (2016-2027)
Figure 37. Asia-Pacific IBS Treatment Market Share by Application (2016-2027)
Figure 38. Asia-Pacific IBS Treatment Market Share by Region (2016-2027)
Figure 39. China IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America IBS Treatment Market Share by Type (2016-2027)
Figure 47. Latin America IBS Treatment Market Share by Application (2016-2027)
Figure 48. Latin America IBS Treatment Market Share by Country (2016-2027)
Figure 49. Mexico IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa IBS Treatment Market Share by Type (2016-2027)
Figure 53. Middle East & Africa IBS Treatment Market Share by Application (2016-2027)
Figure 54. Middle East & Africa IBS Treatment Market Share by Country (2016-2027)
Figure 55. Turkey IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE IBS Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Allergan Plc (Ireland) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 59. Sucampo Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 60. Ironwood Pharmaceuticals, Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 61. Astellas Pharma Inc. (Japan) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 62. Bausch Health Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 63. Abbott Laboratories (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 64. Synergy Pharmaceuticals, Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 65. Ardelyx, Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 66. Nestle (Switzerland) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 67. Sebela Pharmaceuticals (Ireland) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 68. Probi (Sweden) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 69. Alfasigma USA, Inc. (Italy) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 70. RedHill Biopharma Ltd. (Israel) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 71. AstraZeneca (U.K) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 72. Ipsen (France) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 73. Novartis AG (Switzerland) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 74. Takeda Pharmaceutical Company Ltd (Japan) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 75. Synthetic Biologics, Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 76. Protagonist Therapeutics Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 77. Pfizer Inc (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 78. Lexicon Pharmaceuticals, Inc. (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 79. Innovate Biopharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2016-2021)
Figure 80. Bottom-up and Top-down Approaches for This Report
Figure 81. Data Triangulation
Figure 82. Key Executives Interviewed
世界のレーシック治療市場規模・現状・予測（2021年-2027年） Laser-assisted in situ keratomileusis, or LASIK, is a form of laser eye surgery that alters the shape of the cornea to reduce or eliminate the need for glasses and contact lenses in case of severe myopia (nearsightedness). This surgery acts as a long-term alternative to contact lenses and eyeglasses…- 世界の気管支炎治療市場規模・現状・予測（2021年-2027年） Bronchitis is a respiratory disease in which there is inflammation of the bronchi in the lungs. In other words, bronchitis is an inflammation of the lining of bronchial tubes that carry air to and from the lungs. Some of the common signs and symptoms of bronchitis include cough, fatigue, shortness o…
- 世界のハンセン病治療市場規模・現状・予測（2021年-2027年） Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacterium Mycobacterium leprae or Mycobacterium lepromatosis. Initially, infections are without symptoms and typically remain this way for 5 to 20 years. Symptoms that develop include granulomas of the nerves, respiratory …
- 世界の末端黒子型黒色腫治療市場規模・現状・予測（2021年-2027年） Acral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Market Analysis and Insights: Global Acral Lentiginous Melanoma Treatment Market The global Acral Lentiginous …
- 世界の胃炎治療薬市場規模・現状・予測（2021年-2027年） Gastritis is inflammation of the lining of the stomach. It may occur as a short episode or may be of a long duration. There may be no symptoms but, when symptoms are present, the most common is upper abdominal pain. Other possible symptoms include nausea and vomiting, bloating, loss of appetite and …